Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Anti-KRAS G12D TCR cells |
Trade Name | |
Synonyms | Anti-KRAS G12D T-cell receptor cells |
Drug Descriptions |
Anti-KRAS G12D TCR cells are autologous T-cells engineered to express HLA-C*08:02-restricted T-cell receptors (TCR) targeting KRAS G12D, potentially leading to inhibition of tumor growth (PMID: 35648703). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Aldesleukin Anti-KRAS G12D TCR cells GRT-C903 GRT-R904 | 0 | 1 |
Anti-KRAS G12D TCR cells | Anti-KRAS G12D TCR cells | 0 | 0 |